Business
Proposed Issue of Equity and Grant of Options
Physiomics plc announced the conditional issue of new ordinary shares and the grant of options to its directors as part of its remuneration policy. Chairman Nick Tulloch will receive 4,000,000 new ordinary shares valued at £20,000, while Executive Director Mike Whitlow and Finance Director Ian Bagnall will each receive 5,000,000 new ordinary shares valued at £25,000, all issued at 0.50 pence per share. Additionally, directors were granted options for a total of 20,139,858 ordinary shares, with 10,909,089 options exercisable at 0.55 pence and 9,230,769 at 0.65 pence, representing premiums to the recent market price. These equity awards are intended to conserve cash and align director incentives with shareholder interests. Disclaimer*
About this update from Physiomics Plc
30 June 2026 Physiomics plc ("Physiomics" or the "Company") Proposed Issue of Equity and Grant of Options Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces the conditional issue of new ordinary shares of 0.40 pence each in Physiomics (the "Ordinary Shares") in respect of the board of directors of Physiomics' (the "Board" or the "Directors") remuneration policy as announced on 8 May 2026, whereby each Director is remunerated partially through the issue of new Ordinary Shares. Nick Tulloch, Chairman, will receive 4,000,000 new Ordinary Shares, representing remuneration of £20,000. Mike Whitlow, Executive Director, and Ian Bagnall, Finance Director, will each receive 5,000,000 new Ordinary Shares, representing remuneration of £25,000. All of the new Ordinary Shares are to be issued at a price of 0.50 pence per new Ordinary Share, being the closing price on 28 April 2026, the day before the Directors joined the Board. It is intended that awards of Ordinary Shares to Directors will be made once in each financial year in respect of part of their remuneration. As the Company currently has no headroom to issue new Ordinary Shares, the above share awards to the Directors will be made following the Company's next annual general meeting ("AGM") at which resolutions will be proposed to grant authorities for the issue of the new Ordinary Shares and the Options described below. Physiomics further announces the grant of options ("Options") to Directors for a total of 20,139,858 Ordinary Shares. Each Option provides the holder with the right to receive one new Ordinary Share on its exercise. 10,909,089 of the Options were granted with an exercise price of 0.55 pence per new Ordinary Share and 9,230,769 of the Options were granted with an exercise price of 0.65 pence per new Ordinary Share, representing a premium of approximately 15 per cent. and approximately 35 per cent. respectively to the mid-market closing price of 0.48 pence per Ordinary Share on 26 June 2026. The Options in aggregate will represent 4.3 per cent of the Company's share capital, ceteris paribus, as enlarged by the issue of the New Ordinary Shares above. Th...